Samjin Pharmaceutical

삼진제약 · 005500

Health Care Pharmaceuticals · KOSPI

Small-cap

Market cap US$188.7M (₩260.4B)

Overview

Samjin Pharmaceutical makes prescription and over-the-counter medicines supplied to hospitals, clinics, and pharmacies across South Korea.

It is listed on KOSPI, South Korea's main stock exchange. The filing covers a broad product and services portfolio alongside active research and development activity, suggesting the business spans both established drug lines and pipeline work.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$224M

▲ +0.3% YoY

Operating profit · FY2025

US$19.4M

▼ −15.3% YoY

Net income · FY2025

US$17.5M

▼ −38.4% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$211.7M(₩292.1B)	US$223.4M(₩308.3B)	US$224M(₩309.1B)
Operating profit	US$14.8M(₩20.5B)	US$22.9M(₩31.6B)	US$19.4M(₩26.8B)
Net income	US$13.7M(₩18.9B)	US$28.4M(₩39.2B)	US$17.5M(₩24.2B)

Revenue

FY2023US$211.7M
FY2024US$223.4M
FY2025US$224M

Operating profit

FY2023US$14.8M
FY2024US$22.9M
FY2025US$19.4M

Net income

FY2023US$13.7M
FY2024US$28.4M
FY2025US$17.5M

Key ratios (FY2025)

ROE

8.3%

Debt/Eq

62.0%

Op. margin

8.7%

Net margin

7.8%

Rev. YoY

▲ +0.3%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?